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Abstract
Background: Tick-borne encephalitis virus (TBEV) is a member of the Flaviviridae family, Flavivirus genus, which
includes several important human pathogens. It is responsible for neurological symptoms that may cause
permanent disability or death, and, from a medical point of view, is the major arbovirus in Central/Northern Europe
and North-Eastern Asia. TBEV tropism is critical for neuropathogenesis, yet little is known about the molecular
mechanisms that govern the susceptibility of human brain cells to the virus. In this study, we sought to establish
and characterize a new in vitro model of TBEV infection in the human brain and to decipher cell type-specific
innate immunity and its relation to TBEV tropism and neuropathogenesis.
Method: Human neuronal/glial cells were differentiated from neural progenitor cells and infected with the TBEV-Hypr
strain. Kinetics of infection, cellular tropism, and cellular responses, including innate immune responses, were characterized
by measuring viral genome and viral titer, performing immunofluorescence, enumerating the different cellular types, and
determining their rate of infection and by performing PCR array and qRT-PCR. The specific response of neurons and
astrocytes was analyzed using the same approaches after enrichment of the neuronal/glial cultures for each cellular subtype.
Results:We showed that infection of human neuronal/glial cells mimicked three major hallmarks of TBEV infection in the
human brain, namely, preferential neuronal tropism, neuronal death, and astrogliosis. We further showed that these cells
conserved their capacity to mount an antiviral response against TBEV. TBEV-infected neuronal/glial cells, therefore,
represented a highly relevant pathological model. By enriching the cultures for either neurons or astrocytes, we further
demonstrated qualitative and quantitative differential innate immune responses in the two cell types that correlated with
their particular susceptibility to TBEV.
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Conclusion: Our results thus reveal that cell type-specific innate immunity is likely to contribute to shaping TBEV tropism for
human brain cells. They describe a new in vitro model for in-depth study of TBEV-induced neuropathogenesis and improve
our understanding of the mechanisms by which neurotropic viruses target and damage human brain cells.
Keywords: Neurotropic virus, Flavivirus, Tick-borne encephalitis virus, Central nervous system, Human neuronal/glial cells,
Viral tropism, Innate immunity, Neuropathogenesis, Pathological modeling
Background
Tick-borne encephalitis virus (TBEV) belongs to the
genus Flavivirus (family Flaviviridae), whose members
include several important human pathogens transmitted
by arthropods, such as Japanese encephalitis virus (JEV),
West Nile virus (WNV), Zika virus (ZIKV), and Powas-
san virus (POWV). From a medical point of view, TBEV
is the most important arbovirus in Europe and North-
Eastern Asia. Its endemic zone spreads from Northern,
Central, and Eastern Europe to Far East Asia [1]. It in-
duces a range of symptoms from mild flu-like symptoms
to severe encephalitis and paralysis, often with long-term
neurological sequelae [2]. The incidence of the disease
has increased in recent decades, and autochthonous
cases are regularly reported in new areas of Western
Europe, reflecting an expansion to non-endemic areas
[3]. Despite commercialization of an effective vaccine
[4], between 8000 and 13,000 annual cases of tick-borne
encephalitis have been reported worldwide since the
1990s [5]. No therapy is currently available [6].
TBEV is usually transmitted to humans from infected
ticks, mainly of the Ixodes family, but may occasionally
be acquired by consumption of unpasteurized dairy
products from infected livestock [7–9]. Upon inoculation
into the human skin, initial infection and replication
occur in local dendritic cells (DCs). DCs are believed to
transport the virus to draining lymph nodes from which
it spreads into the bloodstream and induces viremia. It
may then cross the blood-brain barrier and cause wide-
spread lesions in the brain. These include inflammatory
changes, neuronal damage, and glial reactivity in several
brain areas, including the spinal cord, brainstem, cere-
bellum, and striatum [10, 11]. Neurons are the primary
target of infection [12], but other cells in the central ner-
vous system (CNS) may contribute to TBEV-induced
neuropathogenesis. Both infiltrating immunocompetent
cells, mainly CD8+ T cells, and resident glial cells, such
as astrocytes and microglial cells, have been shown to
play a role [13, 14]. Neuronal damage may thus be medi-
ated directly by viral infection or indirectly by infiltrating
immunocompetent cells, inflammatory cytokines, and
activated resident glial cells.
The innate immune response is the first line of defense
against viral infection. Type I interferons (IFNs) are of
particular importance in this process. Through binding
to the IFN alpha/beta receptor (IFNAR), they act via
autocrine or paracrine signaling [15–17] and trigger the
activation of a large number of interferon-stimulated
genes (ISGs) that can inhibit almost every step of the
viral life cycle [18]. In recent years, it has become clear
that parenchymal cells of the CNS play a major role in
the development of the innate immune response and the
protection of infected individuals after CNS infection
[19–24]. Neurons and astrocytes are not passive targets,
as they are known to produce and respond to type I
IFNs. Nevertheless, the innate immune programs acti-
vated in these cell types during TBEV infection and their
impact on viral tropism and neuropathogenesis remain
poorly known.
Animal models have been widely used to elucidate the
cellular and molecular mechanisms of TBEV-induced
neuropathogenesis [2]. Nevertheless, the results obtained
from such studies may be difficult to transpose to hu-
man neuropathogenesis, as human antiviral responses
differ substantially from those of other mammalian spe-
cies [25, 26]. The biological relevance of models based
on human CNS cells is thus increasingly recognized.
These include neuronal/glial cell lines, primary neur-
onal/glial cells from human fetuses, and more recently,
neuronal/glial cells derived from fetal neural progenitors
(hNPCs), embryonic (hESCs), or induced pluripotent
stem cells (hiPSCs). While primary human CNS cells are
physiologically more relevant than cell lines, their use is
limited by the difficulty in gaining access to cell sources.
On the other hand, neuronal/glial cultures derived from
neural progenitors are not only physiologically relevant,
but also have the advantage of being available on de-
mand. In recent years, they have become important tools
to study neurotropic viruses [27].
The goal of this study was, first, to set up and
characterize a new in vitro model of TBEV infection
using complex co-cultures of hNPC-derived neuronal/
glial cells and, second, to decipher cell-specific anti-
TBEV immunity in the human CNS and its relation to
TBEV tropism and neuropathogenesis. We showed that
in vitro TBEV infection mimics several hallmarks of
in vivo infection, including marked neuronal tropism
and neuronal death, limited astrocyte susceptibility,
astrogliosis, and induction of an antiviral response.
Moreover, we demonstrated differential qualitative and
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quantitative antiviral capacities in human neurons and
astrocytes that are correlated with their susceptibility to
TBEV infection. Finally, we showed that human astro-




Human fetuses were obtained after legal abortion with
written informed consent from the patient. The proced-
ure for the procurement and use of human fetal central
nervous system tissue was approved and monitored by
the “Comité Consultatif de Protection des Personnes
dans la Recherche Biomédicale” of Henri Mondor Hos-
pital, France. The cells are declared at the “Centre de
Ressources Biologiques” of the University Hospital in
Angers BB-0033-00038 with reference numbers at the
Research Ministry: declaration no. DC-2011-1467 and
authorization no. AC-2012-1507.
The rabbit immunization protocol complied with EU
legislation (authorization 12/04/11-6 given by the
ANSES/ENVA/UPEC ethical committee).
Culture of human neural progenitor cells
Human neural progenitor cells (hNPCs) were prepared
and cultured as previously described in [28, 29]. They
are self-renewing cells and therefore may provide an un-
limited source of material.
Neuronal and glial differentiation
hNPCs were seeded on matrigel-coated plates at a dens-
ity of 30,000 cells/cm2. Differentiation into a mixed
population of neuronal and glial cells was induced 24 h
after plating by replacing N2A medium with 1:1 N2A
and NBC media (N2A: advanced Dulbecco’s modified
Eagle medium-F12 supplemented with 2 mML-glutam-
ine, 0.1 mg/ml apotransferrin, 25 μg/ml insulin, and 6.3
ng/ml progesterone; NBC: neurobasal medium supple-
mented with 2mM L-glutamine and B27 without vita-
min A 1X—Invitrogen, Life Technologies) and
withdrawing EGF (TEBU, France) and bFGF (TEBU,
France). Differentiation conditions were maintained for
13 days with medium replacement twice a week, prior to
infection. Twenty-four-well plates (IBIDI, #82406) were
used for fluorescent immunostaining, and 6-well plates
(Falcon) were used to prepare lysates for RNA analyses.
Virus and infection
TBEV-Hypr strain was a kind gift from Dr. S. Moutailler
(Maisons-Alfort, France). The strain was isolated in 1953
from the blood of a 10-year-old child in the Czech Re-
public, and the complete sequence was published in
[30]. A working stock was generated in VERO cells
(VERO-ATCC-CCL81) cultured in MEM medium
(ThermoFisher) supplemented with 2% fetal bovine
serum (FBS). Titer was estimated by plaque assay on
VERO cells. Neuronal/glial cells differentiated for 13
days were infected with the virus (MOI 10−2) for 1 h at
37 °C. The inoculum was removed and cells were incu-
bated in fresh N2A-NBC medium. Virus titers were esti-
mated by endpoint dilution on VERO cells (TCID50).
All procedures with infectious materials were performed
under bio-safety level-3 (BSL-3) conditions.
RNA isolation and qPCR
RNA was isolated from infected and non-infected neur-
onal/glial co-cultures. Cells were lysed using the Nucleo-
Mag® 96 RNA kit (Macherey Nagel), and RNA was
extracted with a King Fisher Duo automat (Fisher Scien-
tific) following the manufacturer’s instructions. Extrac-
tion of viral RNA from supernatants of infected cells
was performed using QIAamp Viral RNA Mini Kit (Qia-
gen) according to the manufacturer’s instructions. One
hundred and sixty nanograms (Fig. 5) or 250 ng (Figs. 7
and 1d) of RNA from cell lysates and 2 μl of RNA from
supernatant (Fig. 1d) were used to synthesize cDNA with
the SuperScript™ II Reverse Transcriptase kit (Thermo-
Fisher Scientific). Real-time PCR was performed using
2 μl of cDNA and QuantiTect SYBR green PCR master
(Qiagen) with a LightCycler 96 instrument (Roche Ap-
plied Science), for a total volume of 20 μl of reaction
mixture. For relative quantification, the − 2ΔΔCt method
was used [31]. The reference genes were GAPDH or
HPRT1. Primers pairs are listed in Additional file 1.
TBEV primers pairs were from Schwaiger et al. [32].
RT2 profiler PCR array
Equal volumes of RNA from biological triplicates were
pooled for each condition. Two hundred to 500 ng of
RNA were transcribed with the RT2 First Strand Kit (SA
Biosciences, Qiagen). Synthetized cDNA was subjected
to a PCR array specific for the human antiviral response
(RT2 Profiler PCR array—PAHS-122Z, SA Biosciences,
Qiagen), according to the manufacturer’s instructions.
Data were normalized using the HPRT1 house-keeping
gene and analyzed with the − 2ΔΔCt method for relative
quantification. According to the manufacturer’s instruc-
tions, an arbitrary cut-off of 3 was applied to determine
significant differences. The analysis was performed using
the Qiagen Data analysis center (http://www.qiagen.
com/fr/shop/genes-and-pathways/data-analysis-center-
overview-page/).
Immunofluorescence assays and cell enumeration
Neuronal/glial cells were fixed for 20 min in 4% parafor-
maldehyde in PBS (Electron Microscopy Sciences) and
standard immunofluorescence was performed using anti-
bodies for HuC/HuD (Thermofisher #A21271), βIII-
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tubulin (Sigma #T8660), GFAP (Dako #M076101-2 or
#Z033429-2), OLIG2 (R&D Systems #AF2418), and
TBEV-E3. TBEV-E3 antibody was produced as follows: a
rabbit polyclonal antiserum was raised against the TBEV
E domain 3 after 3 sequential immunizations of 3-
months old New Zealand rabbits with 100 μg of Ni2+-
resins affinity-purified antigen adjuvanted with ISA50V2
(SEPPIC, France) at a 3-week interval and was collected
on week 8 after the prime. The production of affinity-
purified TBEV E domain 3 has been detailed in Beck
et al. [33]. Cells were blocked for 1 h in 3% BSA (Sigma),
0.3% Triton-X-100 (VWR) in PBS 1X and primary anti-
bodies were diluted in 1% BSA, 0.1% Triton-X-100 in
PBS 1X, and incubated overnight at + 4 °C. Secondary
antibodies were Alexa Fluor-488/546-conjugated anti-
mouse/anti-rabbit IgG (Molecular Probes, Invitrogen).
Nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI) (Life Technologies) at 0.1 ng/ml. For the assess-
ment of apoptotic cell death, terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling (TUNEL) staining was performed according
to the manufacturer’s instructions (Promega, France).
Cell sub-types and infected cells were enumerated either
manually or automatically. For manual cell quantifica-
tion (cells immunostained with antibodies directed
against βIII-tubulin and GFAP), images were acquired
with an AxioObserver Z1 (Zeiss) inverted microscope
using ZEN software (Zeiss) and analyzed using ImageJ
1.49 m software. For automated quantification (cells im-
munostained with antibodies directed against HuC/
HuD, TBEV-E3 and OLIG2, neurites immunostained
with an antibody against βIII-tubulin- and TUNEL-
stained cells), images were acquired using the Cellomics
ArrayScan automated microscope (Thermofisher Scien-
tific) and analyzed using “Colocalization” or “Neuronal
profiling” bio-applications on HCS Studio Cell Analysis
Software V6.6.0 (Thermofisher Scientific). In all experi-
ments, an average of 1200 (manual quantification) or
5000 (automated quantification) cells per well were enu-
merated. The digitized images shown were adjusted for
brightness and contrast using ImageJ, without further
alteration.
Magnetic-activated cell sorting
Neuronal/glial cells differentiated for 13 days were de-
tached using Gibco™ TrypLE™ Select Enzyme (1X) and
Fig. 1 TBEV infects, replicates, and spreads in hNPC-derived brain cells. a Schematic representation of the experimental procedure. b
Immunofluorescence labeling of differentiated hNPCs 24 h and 72 h following TBEV infection. An antibody directed against the domain 3 of the
viral envelope (TBEV-E3, green) revealed infected cells. Nuclei were stained with DAPI (blue). c Enumeration of infected cells based on
immunofluorescence labeling using an ArrayScan Cellomics instrument. d RNA from the supernatant and cell lysate of infected cells was analyzed
by RT-qPCR to determine viral replication. e Supernatant was collected at 14, 48, and 72 hpi and titrated by endpoint dilution (TCID50) on VERO
cells. Results are representative of 3 independent experiments performed in triplicate. Data are expressed as the mean ± SD. Statistical analysis
was performed using one-way ANOVA (Bonferroni’s Multiple Comparison Test) with Graphpad Prism V6.0.1. ns, non-significant (p > 0.05); **p <
0.01, ***p < 0.001. Scale bar = 100 μm
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collected into N2A-NBC medium. After centrifugation
at 80×g for 10 min, cells were either sub-cultured (Uns-
C) or supplemented with kynurenic acid buffer and
sorted according to the manufacturer’s instructions
using the Microbead Kit (Miltenyi Biotec #130–095-
826). In brief, resuspended cells were incubated for 10
min at 4 °C with 20 μl biotin-conjugated anti-GLAST
(ACSA-1) antibodies per 107 cells, washed, and incu-
bated with anti-biotin MicroBeads for 15 min at 4 °C.
Cell sorting was performed using MS columns (Miltenyi
Biotec, #130-042-201) placed in a MiniMACS™ separator
(Miltenyi Biotec #130-090-312). The cell fractions found
in the flow-through or bound to beads were composed
of enriched neurons (En-N) and enriched astrocytes (En-
As), respectively. Both sorted and unsorted cells were
seeded at a density of 100,000 cells per cm2 on 24-well
μ-plates (IBIDI, #82406) in N2A-NBC or conditioned
medium (1:1, fresh N2A-NBC: supernatant of non-
infected co-cultures differentiated for 13 days, condi-
tioned for 48 h). Conditioned medium allowed neuronal
survival in En-N cultures. Half of the medium was re-
placed every other day.
Statistical analyses
Data are represented as mean ± standard deviation (SD).
Statistical analyses were performed with GraphPad
Prism V4.03 or V6.0.1 using an unpaired Student’s t test
or a one-way ANOVA analysis (Bonferroni’s multiple
comparison test), *p < 0.05, **p < 0.01, ***p < 0.001, non-
significant (ns) = p > 0.05.
Results
TBEV infects brain cells differentiated from human fetal
neural progenitors
HNPCs and their derived neuronal/glial cells were previ-
ously set up in our laboratory for the study of Borna dis-
ease virus, a neurotropic virus that belongs to the
Bornaviridae family [28, 29]. Here, we used the same
hNPCs prepared according to the experimental steps
summarized in Fig. 1a. HNPCs were differentiated for
13 days, by which time all neurons were generated [29],
before infection with the TBEV-Hypr strain at MOI
10−2. Infected neuronal/glial co-cultures were then ana-
lyzed over time. We first examined the capacity of the
virus to infect, replicate, and disseminate within the co-
culture. Examination of cells immunostained with an
antibody specific for domain 3 of the TBEV envelope
protein (TBEV-E3), at 24 and 72 h post-infection (hpi),
revealed that TBEV entered human brain cells and
spread within the co-culture (Fig. 1b). Enumeration of
infected cells from 14 hpi to 7 dpi showed that 7.3 ±
0.7% of cells were indeed infected at 14 hpi, whereas
45.0 ± 4.0% were infected at 72 hpi, at the peak of infec-
tion (Fig. 1c). At a later time, 7 dpi, the number of
infected cells decreased. A similar pattern of infection
was observed when the viral RNA was quantified by RT-
qPCR, whether in the supernatant or intracellularly,
from 14 hpi to 7 dpi (Fig. 1d), with an increase in viral
RNA observed up to 48–72 hpi followed by a decrease
from 96 hpi to 7 dpi. This confirmed active replication
of the virus in hNPC-derived brain cells. Quantification
of viral titer by endpoint dilution further showed that in-
fectious particles were released into the supernatant and
increased from 14 hpi to 48 hpi and 72 hpi (Fig. 1e).
Thus, the infection, replication and dissemination of
virus were efficient in hNPC-derived neuronal/glial cells.
TBEV infects human neurons, astrocytes, and
oligodendrocytes
We next sought to determine which neural subsets were
infected by TBEV in neuronal/glial co-cultures. We had
previously shown that, upon growth factor withdrawal,
hNPCs differentiated into GABAergic neurons and as-
trocytes [28, 29]. Oligodendrocytes, the third cell type
that can be generated by differentiation of hNPCs, were
not taken into consideration. Of note, microglial cells,
which are of mesodermic origin, cannot be generated
from fetal neural progenitor cells. To gain in precision,
in the present study, we enumerated all 3 cell types,
based on immunofluorescence staining (see Additional
file 2A), 13 and 21 days after the onset of differentiation.
Automatic enumeration of immunostained cells with
antibodies directed against HuC/HuD (nuclear markers
for neurons) and OLIG2 (nuclear marker for oligoden-
drocytes) revealed a population composed of 77.0 ± 3.2%
(d13) and 74.1 ± 5.4% (d21) neurons and 1.4 ± 1.0% (d13)
and 3.7 ± 1.0% (d21) oligodendrocytes (see Additional
file 2B). Due to technical limitations (GFAP localization
in astrocytic outgrowths and unavailability of a nuclear
marker), astrocytes could not be automatically enumer-
ated. The remaining population, namely total cells minus
neurons and oligodendrocytes, comprising 21.5 ± 4.1%
(d13) and 22.2 ± 4.4% (d21) of cells, was therefore con-
sidered to be composed of astrocytes (see Additional file
2B). The reliability of this enumeration procedure was
confirmed by manual enumeration, as 22.8 ± 5.6% (d13)
and 32.7 ± 5.0% (d21) of astrocytes were found using this
method (see Additional file 2C). Thus, we confirmed
that neurons and astrocytes were the major cell types in
our co-cultures and showed that oligodendrocytes con-
stituted less than 5% of the total cell population.
To characterize TBEV cellular tropism, we infected
hNPC-derived neuronal/glial co-cultures and followed
infection from 14 h to 7 days. Cells were co-
immunostained with antibodies directed against TBEV-
E3 (infected cells) and βIII-tubulin or HuC/HuD (neu-
rons), GFAP (astrocytes) and OLIG2 (oligodendrocytes).
At 24 hpi, the 3 cell types were infected, as shown in
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Fig. 2a. Viral envelope strongly accumulated in the peri-
nuclear region of the cytoplasm in all cell types. The
protein could also be evidenced in certain neurites and
astrocyte outgrowths, albeit with a lower intensity (Fig.
2b). We then sought to determine whether the virus
spread within each cellular subpopulation. We therefore
quantified infection in each cell type, at different time
points during the course of the study (Fig. 2c–e). The
general profile of infection at onset was similar in the 3
cell types, with an increase in the first days of infection
up until a peak occurring at 48–72 hpi. While this phase
was followed by a decrease from 96 hpi onwards in the
neuronal population, the percentage of infection
remained stable in astrocytes and oligodendrocytes, at
least up to 7 dpi. Early in infection, at 14 hpi, a minority
of cells were infected within each subset, namely 7.9 ±
1.2% of neurons, 4.3 ± 1.5% of astrocytes, and 11.7 ± 0.8%
of oligodendrocytes. Later, however, at the peak of infec-
tion, the proportion of infected cells was high in neurons
(55.2 ± 3.8%) and oligodendrocytes (68.0 ± 21.5%) but
much lower in astrocytes (13.6 ± 5.3%), revealing differ-
ential propagation of the virus within the three sub-
populations. Thus, whereas human neurons and oligo-
dendrocytes were highly susceptible to TBEV infection,
human astrocytes were more resistant.
TBEV induces death of neurons and astrocytes
As hNPC-derived neuronal/glial cells were highly in-
fected, we then sought to evaluate whether TBEV in-
duced cellular damage. Cultures were infected, and cells
were fixed at several time points from 14 hpi to 14 dpi
before immunostaining with antibodies specific for neur-
onal and glial cells, as previously described. We first ex-
amined the neuronal population. At 14 dpi, examination
of HuC/HuD immunostaining revealed that TBEV-
infected co-cultures were strongly depleted in neurons,
as compared with their non-infected matched controls
(Fig. 3a). Enumeration showed that neuronal survival
was unaffected in the first days of infection (from 14 to
48 hpi) but confirmed that neuronal loss occurred as
early as 72 hpi (25.1 ± 5.4% loss) and steadily increased
from this point on, reaching 72.0 ± 10.3% at 14 dpi, the
latest time point of our study (Fig. 3b). We then exam-
ined neuronal morphology based on βIII-tubulin immu-
nostaining. At 7 dpi, a striking loss of neurites was
observed in TBEV-infected cultures as compared with
their non-infected matched controls (Fig. 3c). Quantifi-
cation of total neurite length confirmed their loss not
only at 7 dpi (76.1 ± 21.6% decrease), but also at 72 hpi
(62.0 ± 22.6% decrease), whereas they were unaffected at
an earlier time point (14 hpi) (Fig. 3d). Of note, whereas
neuronal death became progressively more pronounced
between 72 hpi and 7 dpi, neurite loss was as high at 72
hpi as at 7 dpi, suggesting that neurites alteration
precedes neuronal death. In an attempt to determine the
molecular mechanisms responsible for neuronal loss, we
performed TUNEL staining at 24 and 72 hpi. Whereas
there was no difference at 24 hpi, an increase in TUNEL
staining was observed at 72 hpi in TBEV-infected cells
as compared with their matched non-infected controls
(Fig.3e, f), revealing that apoptotic events occurred as
early as 72 hpi. Co-immunostaining with anti-βIII-
tubulin antibody further demonstrated that apoptotic
cells were neurons (Fig. 3e, right panel). Taken together,
these results showed that TBEV infection strongly im-
paired neuronal survival in the co-cultures and, more-
over, suggested that neurite alteration preceded
neuronal death. They also explained the decrease in the
percentage of infected cells and viral RNA at 7 dpi as
shown in Fig. 1c/d. Indeed, as neurons represented the
most numerous and highly infected cells, their massive
death by that time point would have inevitably dimin-
ished the percentage of total infected cells.
We next evaluated whether glial cells were damaged.
Examination of astrocytes immunostained with an anti-
body directed against GFAP at 7 dpi revealed hyper-
trophic cells in TBEV-infected cultures, as compared
with their non-infected matched controls (Fig. 4a). This
change in morphology is reminiscent of astrogliosis, a
common feature of stressed astrocytes. Enumeration of
GFAP-positive cells was then carried out at 24 hpi, 72
hpi, and 7 dpi. Their number was not significantly al-
tered at the earlier time points, 24 hpi and 72 hpi, but a
decrease of 20.7 ± 11.1% was observed at 7 dpi compared
with non-infected matched controls (Fig. 4b). Thus,
TBEV infection diminished survival of not only neurons
but also astrocytes, although in a more moderate man-
ner for the latter. By contrast, enumeration of OLIG-2-
positive cells did not reveal a significant difference in
oligodendrocyte number in TBEV-infected and non-
infected cultures (Fig. 4c), showing that despite direct
TBEV infection, survival of oligodendrocytes was un-
affected. Taken together, our results demonstrated that
subsets of hNPC-derived brain cells, that is, neurons, as-
trocytes, and oligodendrocytes, were differentially af-
fected by TBEV infection. In particular, neurons were
highly susceptible as regards both infection and mortal-
ity, whereas astrocytes were more resistant. Oligoden-
drocytes were susceptible to infection, but their survival
was unaffected.
Human NPC-derived neuronal/glial co-cultures develop a
strong antiviral response to TBEV infection
When infected with virus, cells initiate an antiviral re-
sponse that aims at controlling viral replication. In
order to determine whether the human neuronal/glial
cells used in our study had conserved the capacity to
develop such a response upon TBEV infection, we
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analyzed the differential expression of 84 human
genes involved in the antiviral response, using a PCR
array approach. Transcripts from hNPC-derived neur-
onal/glial cells infected with TBEV for 24 h were
pooled from biological triplicates and compared with
transcripts from their matched non-infected controls.
The studied genes are shown in Fig. 5a and Add-
itional file 3. After applying an arbitrary cut-off of
threefold, 25 genes were shown to be significantly
modulated in TBEV-infected cells, among which 22
genes were upregulated and 3 were downregulated
(Fig. 5a). The former category included pathogen rec-
ognition receptors (PRRs), cytokines, including IFN-β,
and ISGs. Upregulation of nine of these genes, 3
PRRs—IFIH1/MDA5 (Fig. 5b), DDX58/RIG-I (Fig. 5c),
and TLR3 (Fig. 5d); 3 pro-inflammatory cytokines—
Fig. 2 TBEV tropism for hNPC-derived brain cells. HNPCs differentiated for 13 days were infected with TBEV-Hypr at MOI 10−2. a
Immunofluorescence labeling of infected cells at 24 hpi. Antibodies against βIII-tubulin (neurones), GFAP (astrocytes), or OLIG2 (oligodendrocytes)
(green), and TBEV-E3 (red) were used. Nuclei were stained with DAPI (blue). Yellow arrows show infected neurons, astrocytes, and
oligodendrocytes. Digital higher magnification is shown in the right panel. Oligodendrocytes were recolored from gray to green. Scale bar =
20 μm. b Higher magnification (digitally cropped) showing the viral envelope in perinuclear areas (arrowhead) and neurites and astrocytic
outgrowths (arrows). Scale bar = 20 μm. c–e Percentage of infected cells based on immunofluorescence labeling during the course of infection
for (c) neurons, (d) astrocytes, and (e) oligodendrocytes. Results are representative of at least 2 independent experiments performed in triplicate.
Data are expressed as the mean ± SD. Statistical analysis was performed using a two-tailed unpaired t test with Graphpad Prism V6.0.1. ns, non-
significant (p > 0.05); *p < 0.05, **p < 0.01, ***p < 0.001
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CXCL10 (Fig. 5e), CCL5/RANTES (Fig. 5f), and
CXCL11 (Fig. 5g); and 3 ISGs—OAS2 (Fig. 5h), MX1
(Fig.5i), and ISG15 (Fig. 5j), was confirmed using RT-
qPCR. IFI6 (Fig. 5k), an additional ISG that was re-
cently shown to protect cells from Flavivirus infection
[34], was also shown to be upregulated. For most of
these genes, kinetic analyses further revealed that
their expression was activated as early as 7 hpi and
progressively increased during the course of infection
up to 14 dpi, with the exception of pro-inflammatory
cytokines whose expression abruptly decreased at 14
dpi (Fig. 5e–g). The latter, however, remained highly
upregulated, as compared with their matched non-
infected controls. These data indicated that TBEV-
infected hNPC-derived neuronal/glial cells had the
capacity to respond to TBEV infection by developing
a strong and lasting antiviral response.
Differential antiviral response in human neurons and
human astrocytes
Neurons and astrocytes are both known to participate in
the antiviral response in the CNS [20, 35]. As regards ol-
igodendrocytes, little is known so far [36]. Our results,
showing high susceptibility of neurons but resistance of
astrocytes to TBEV infection, led us to hypothesize that
differences in their intrinsic capacity for antiviral defense
might underlie their differential susceptibility. In order
to test this hypothesis and decipher cell-autonomous
anti-TBEV innate immunity in the human CNS, we
sought to obtain cultures enriched in neurons (hence-
forth called En-N) or astrocytes (henceforth called En-
As) and to compare their antiviral response. Oligoden-
drocytes were not considered further in this study, as
their low number in our cultures precluded enrichment.
After differentiation of hNPCs for 13 days, neuronal/glial
Fig. 3 TBEV damages human neurons. HNPCs were differentiated for 13 days and infected with TBEV-Hypr at MOI 10−2. a Cells in non-infected
(NI) and infected (TBEV) co-cultures were immunostained with an antibody directed against HuC/HuD (neurons, green) at 14 dpi. Nuclei were
counterstained with DAPI. Scale bars = 100 μm. b Enumeration of HuC/HuD-positive cells using an ArrayScan Cellomics instrument. Normalization
to non-infected HuC/HuD-positive cells at 14 hpi. c Cells in non-infected and infected cultures were immunostained with an antibody against βIII-
tubulin (neurons, red) at 7 dpi. Note the paucity of neurites in TBEV-infected co-cultures. Scale bars = 100 μm. d Quantification of neurite network
density (neurite length per square millimeter) using an ArrayScan Cellomics instrument. e Cells in non-infected and TBEV-infected cultures were
TUNEL stained at 72 hpi. Note that TUNEL staining matches with βIII-tubulin immunostaining (arrows). Right panel show an apoptotic neuron
(co-localization of βIII-tubulin and TUNEL staining). Scale bars = 20 μm. (f) Percentage of apoptotic cells based on TUNEL staining at 24 and 72 hpi.
Results in b, d, and f are expressed as the mean ± SD and are representative of four (b) and two (d, f) independent experiments performed in
triplicate, respectively. Statistical analysis was performed using a two-tailed unpaired t test with Graphpad Prism V6.0.1. ns, non-significant (p >
0.05); *p < 0.05, **p < 0.01, ***p < 0.001
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cells were trypsinized and either directly re-seeded (un-
sorted cultures henceforth called Uns-C) or enriched for
neurons (En-N) or astrocytes (En-As). We showed that
the splitting procedure did not alter the neuronal/glial
co-cultures (Uns-C). Indeed, 4 days after re-seeding,
phase-contrast microscopy of Uns-C revealed typical
neuronal (small sized with neurites) and astroglial (lar-
ger, flat, with outgrowths) cells (Fig. 6a), as typically ob-
served in non-trypsinized co-cultures (henceforth called
Co-C cells). Immunofluorescence staining using anti-
bodies directed against neurons (HuC/HuD), astrocytes
(GFAP), and oligodendrocytes (OLIG2) markers showed
a mixed population (Fig. 6b) composed of 74.1 ± 4.1%
neurons, 20.8 ± 4.9% astrocytes, and 5.1 ± 1.2% oligoden-
drocytes (Fig. 6c) revealing that the percentage of each
subpopulation was unchanged in Uns-C as compared
with Co-C cells. Basal expression of antiviral genes was
also unchanged, as shown by the analysis of 84 genes of
the antiviral response in Uns-C and Co-C cells (Fig. 6d).
Enrichment in neurons and in astrocytes was confirmed
by phase-contrast microscopy (Fig. 6e and h, respect-
ively) and immunofluorescence staining (Fig. 6f and i, re-
spectively) combined with cell enumeration showing
that the En-N population was composed of 94.1 ± 0.4%
neurons, 3.1 ± 0.4% astrocytes and 2.8 ± 0.2% oligoden-
drocytes (Fig. 6g) while the En-As population comprised
53.5 ± 2.7% astrocytes, 35.7 ± 2.8% neurons, and 10.8 ±
0.5% oligodendrocytes (Fig. 6j).
We then sought to determine whether distinct anti-
viral responses occurred in En-As, En-N, and Uns-C
upon TBEV infection, which would reflect differential
antiviral responses in human neurons and astrocytes.
Cells were infected for 24 h, and the expression of 84
genes of the antiviral response was compared using the
same PCR array as previously described. After applica-
tion of the usual arbitrary cut-off of threefold, 20 genes
in TBEV-infected Uns-C, 16 genes in TBEV-infected En-
N and 21 genes in TBEV-infected En-As were shown to
be significantly upregulated, as compared with their
non-infected matched controls (Fig. 7a and Add-
itional file 4). Among the set of upregulated genes,
which overlapped with that of non-trypsinized co-
cultures, 13 were common to the three cultures (Table 1)
while others were specific for En-As or En-N cultures
(8/21 and 3/16, respectively). Thus, these results showed
that the antiviral program activated by TBEV was par-
tially different in human neurons and astrocytes. Of
note, for 12/13 of common genes, the magnitude of up-
regulation was correlated to the percentage of astrocytes
in the cultures. That is, it was much higher in En-As
than in En-N and intermediary in Uns-C (Fig. 7a, Table
1), showing that human astrocytes were capable of
Fig. 4 Impact of TBEV on human glial cells. HNPCs were differentiated for 13 days and infected with TBEV-Hypr at MOI 10−2. a Cells in non-
infected (NI) and infected (TBEV) co-cultures were immunostained with an antibody directed against GFAP (astrocytes, red) at 7 dpi. Nuclei were
counterstained with DAPI. Scale bars = 20 μm. b Manual enumeration of GFAP-positive cells using ImageJ software. Normalization was performed
relative to non-infected GFAP-positive cells at 24 hpi. c Cells immunostained with OLIG2 antibody were enumerated automatically. Normalization
was performed relative to non-infected OLIG2-positive cells at 24 hpi. The results are expressed as the mean ± SD and are representative of two
(oligodendrocytes) and three (astrocytes) independent experiments performed in triplicate. Statistical analysis was performed using a two-tailed
unpaired t test with Graphpad Prism V6.0.1. ns, non-significant (p > 0.05); *p < 0.05
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developing a stronger antiviral response to TBEV than
human neurons. To validate the PCR array data and to
gain further insight into the kinetics of expression of
antiviral genes in each cell types, we performed RT-
qPCR at 7, 24, and 72 hpi for IFN-β, (Fig. 7b), 3 PRRs—
IFIH1 (MDA5) (Fig. 7c), DDX58 (RIG-I) (Fig. 7d), and
TLR3 (Fig. 7e); two ISGs—OAS2 (Fig. 7f) and MX1 (Fig.
7g); and one pro-inflammatory cytokine—CXCL10 (Fig.
7h). Because of their well-known anti-flavivirus activity,
the ISGs IFI6 (Fig. 7i), RSAD2 (viperin) (Fig. 7j), and
TRIM5α (Fig.7k) were also studied. In confirmation of
the PCR array data, all of these genes were significantly
more upregulated in En-As than in En-N, at both 24
and 72 hpi. In addition, at 72 hpi, gene expression in
En-N was either maintained (RIG-I, TLR3, OAS2,
viperin, CXCL10, TRIM5α, IFN-β) or decreased (MDA5,
MX1, IFI6), while it was either maintained (MDA5,
TLR3, MX1, viperin, TRIM5α, IFN-β) or increased
(RIG-I, OAS2, CXCL10, IFI6) in En-As, showing that
the duration of antiviral responses was shorter in human
neurons than in astrocytes. The induction of an
astrocyte-specific antiviral program, as suggested by the
selective upregulation of 8 genes in En-As (Fig. 7a, Table
1), was further confirmed by the results of RT-qPCR.
Not only TLR3 but also viperin and TRIM5α were
among those genes, as upregulation was observed in En-
As at 24 hpi and 72 hpi but not in En-N at either time
point (Fig. 7e, j, k). Thus, taken together, these results
show that TBEV infection induces an antiviral response
in human neurons and astrocytes that is characterized
by activation of an overlapping set of genes. This anti-
viral program, however, was of greater intensity and
Fig. 5 TBEV-induced antiviral response in hNPC-derived neuronal/glial cells. a TBEV-infected neuronal/glial cells (MOI 10−2) and their matched NI
controls were analyzed 24 hpi using an RT2 Profiler PCR array specific for the human antiviral response. The heat map shows the differential
expression of 84 analyzed human genes. The most highly up- and downregulated genes are colored in red and dark green, respectively. The blue
lines indicate the arbitrary cut-off of 3. Genes between the two lines are considered nonregulated. b–k RT-qPCR analyses of selected antiviral
genes. Gene expression was normalized to HPRT1 gene, and the − 2ΔΔCt method was used for relative quantification (normalization to non-
infected cells at 7 hpi). Data are expressed as the mean ± SD. Results are representative of one experiment performed on pooled triplicates (PCR
array) or two independent experiments performed in triplicate (qPCRs). Statistical analysis was performed using a two-tailed unpaired t test with
Graphpad Prism V6.0.1. ns, non-significant (p > 0.05); *p < 0.05, **p < 0.01, ***p < 0.001
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longer duration in human astrocytes than in human
neurons. The antiviral programs of the two cell types
were also notably distinct, as exemplified by selective up-
regulation of the genes encoding viperin and TRIM5α,
well-known for their anti-TBEV and anti-flavivirus activ-
ities [37–39], in human astrocytes. In sum, our results
revealed a stronger and broader antiviral response in hu-
man astrocytes than in human neurons, in keeping with
their differential susceptibility to TBEV infection, astro-
cytes being more resistant and neurons more
susceptible.
Differential expression of antiviral genes in human
neurons and astrocytes following TBEV infection may
reflect differential baseline expression in the two cell
types. To test this hypothesis, non-infected En-N,
Uns-C, and En-As cells were cultured for 4 days and
transcripts from 3 biological samples in each condi-
tion were pooled and compared using the human
antiviral response PCR array. Antiviral gene expres-
sion in En-N was compared with that of Uns-C (Fig.
7l) and En-As (Fig. 7m). Although in both cases, most
of the immunity-related genes were not differentially
expressed to a significant extent (above the threefold
threshold recommended by the manufacturer), we ob-
served that the general tendency was to a slight over-
expression in astrocytes, since the number of
significantly overexpressed genes increased as the per-
centage of astrocytes increased in the culture, from
Fig. 6 Enrichment of human neurons and astrocytes by magnetic-activated cell sorting. HNPC-derived neuronal/glial cells differentiated for 13
days were sorted using MACS technology. a, e, h Phase-contrast micrographs, showing Uns-C (a), En-N (e), and En-As (h), were acquired 96 h
after re-seeding. Blue arrows indicate neurons and brown arrowheads indicate astrocytes. Scale bars, 50 μm. b, f, i Immunofluorescence staining
with antibodies directed against neurons (HuC/HuD, green), astrocytes (GFAP, red), and oligodendrocytes (OLIG2, gray) markers showing the
mixed and enriched population. DAPI is in blue. Scale bars = 100 μm. c, g, j Enumeration of neurons (Ne), astrocytes (As), and oligodendrocytes
(Ol) in Uns-C (c), En-N (g), and En-As (j) based on immunofluorescence staining and using an ArrayScan Cellomics instrument. Data are
representative of 4 independent experiments performed in triplicate. d Scatterplot of basal level of antiviral response genes in unsorted cells
(Uns-C) compared with non-trypsinized cells (Co-C). Analysis was performed using an antiviral response PCR array. Genes along the black line
have similar expression levels in the two cultures. Dotted lines represent an arbitrary cut-off of 3. Data are from a single experiment performed
with pooled triplicates
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Fig. 7 Antiviral response in enriched neurons, enriched astrocytes, and unsorted cells. a–i Expression of antiviral genes upon TBEV infection. a
TBEV-infected Uns-C, En-N, and En-As (MOI 10−2) and their matched non-infected controls were analyzed 24 hpi using an RT2 profiler PCR array
specific for the human antiviral response. Heat map showing the 84 human genes analyzed and their differential expression. Color code and blue
line are as in Fig. 5. Note that genes noted (+) are above the cut-off of 3. b–k RT-qPCR analyses of selected antiviral response genes in En-As
(red) and En-N (green). l–p Basal expression of antiviral genes. l, m Scatterplots of basal expression levels of antiviral response genes in enriched
neurons (En-N) compared with that of unsorted cells (Uns-C) (l, k) or enriched astrocytes (En-As) (m). Analysis was performed using an antiviral
response PCR array. n–p RT-qPCR analysis of the basal expression of IFIH1/MDA5 (n), DDX58/RIG-I (o), and OAS2 (p) genes in En-N and En-As.
Gene expression was normalized to HPRT1 and the − 2ΔΔCt method was used for relative quantification (normalization to non-infected En-N, at
7hpi for b–k). The results are expressed as the mean ± SD. Data are representative of two independent experiments performed in triplicate (b–k,
n–p) and one experiment performed with pooled triplicates (l, m). Statistical analyses comparing En-As and En-N were performed with Graphpad
Prism V6.0.1 using a two-tailed unpaired t test. ns, non-significant (p > 0.05); *p < 0.05, **p < 0.01, ***p < 0.001
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Uns-C to En-A. Five/84 genes were, indeed, overex-
pressed in Uns-C compared with En-N (Fig. 6l), while
their number rose to 14/84 genes when En-As were
compared with En-N (Fig. 6m). By contrast, very few
of these genes (3/84) were overexpressed in human
neurons, and then only to a modest extent. To valid-
ate these results, differential expression of 3 selected
genes, 2 PRRs (MDA5 and RIG-I) and 1 ISG (OAS2),
was further addressed by RT-qPCR. Significant over-
expression of MDA5 (Fig. 7n) and RIG-I (Fig. 7o) in
En-As as compared with En-N was confirmed. By
contrast, but still in agreement with the PCR array
data, no significant difference was observed for the
OAS2 gene (Fig. 7p). These results thus showed that
the basal level of expression of certain antiviral genes
was higher, albeit slightly, in human astrocytes than
in human neurons.
Human astrocytes protected human neurons from TBEV
infection and TBEV-induced damage
Next, we wondered whether human astrocytes might
participate in neuronal defense. We reasoned that, if this
were the case, neurons would be more sensitive to TBEV
infection in cultures depleted of astrocytes. We therefore
compared neuronal susceptibility and vulnerability to
TBEV infection in Uns-C and En-N, composed of 20.8 ±
4.9% and 3.1 ± 0.4% of astrocytes, respectively. Uns-C
and En-N were infected for 24 h, and the percentage of
TBEV-infected neurons within the total neuronal popu-
lation was quantified based on βIII-tubulin and TBEV-
E3 immunostaining. A 30% increase in infected cells was
observed in En-N compared with Uns-C (Fig. 8a), show-
ing that, in the absence of astrocytes, neurons were more
sensitive to TBEV infection. At that time, neuronal sur-
vival was altered neither in TBEV-infected Uns-C nor in
TBEV-infected En-N, as revealed by observation of βIII-
tubulin immunostaining (Fig. 8b) and enumeration of
neurons (see Additional file 5). At 72 hpi, however, a
more dramatic alteration of neuronal morphology was
observed in TBEV-infected En-N, as compact clusters,
characteristic of intense neuronal death, were formed
(Fig. 8b). Due to these clusters, it was not possible to
enumerate the neurons, but our results clearly showed
that, at 72 hpi, neurons were more dramatically affected
in cultures deprived of astrocytes. Thus, taken together,
these results showed that, upon TBEV infection, the
presence of astrocytes was protective for human
neurons.
Discussion
Despite its importance in human health, TBEV-induced
neuropathogenesis is still poorly understood. So far,
most studies have used either in vitro or in vivo rodent
models, whereas these models have advanced under-
standing, extrapolation to human neuropathogenesis
may not always be relevant, as cellular responses display
profound differences between species [25, 26, 40]. Here
we used neuronal/glial cultures derived from human
fetal neural progenitor cells as a more accurate in vitro
model to study anti-TBEV innate immunity and its rela-
tion to tropism and neuropathogenesis in the human
brain. We developed a new in vitro model that mimics
major hallmarks of TBEV infection in the human brain,
namely neuronal tropism, neuronal death, and astroglio-
sis, thereby providing a unique and highly relevant
pathological model for studying TBEV-induced neuro-
pathogenesis. Moreover, we revealed that a cell type-
specific innate antiviral state in human neurons and as-
trocytes correlates with their differential susceptibility
and vulnerability to TBEV, which strongly suggests that
the innate antiviral response shapes TBEV tropism for
human brain cells.
Table 1 Differential expression of genes involved in the human
antiviral response in unsorted cultures (Uns-C), enriched
neurons (En-N), and enriched astrocytes (En-As). Up- and






CXCL10 1024.0 415.9 1209.3
MX1 367.1 39.1 975.5
CCL5 680.3 265.0 814.6
IFNB1 149.1 71.5 537.5
OAS2 215.3 23.9 498.0
CXCL11 270.6 126.2 388.0
ISG15 61.8 31.8 105.4
IFIH1 32.7 19.7 35.3
DHX58 13.2 10.6 28.2
CASP1 10.5 6.3 24.6
CXCL8 28.4 11.4 23.1
DDX58 10.5 5.7 16.0
IL6 7.4 10.6 8.2
STAT1 5.8 2.5 7.5
TLR3 6.2 1.7 6.4
IRF7 5.0 0.9 5.3
CTSS 4.3 1.3 5.2
TRIM25 3.6 2.2 4.5
AIM2 0.9 1.0 4.0
MYD88 2.4 1.1 3.7
TNF 4.5 2.6 3.7
IL15 3.8 3.3 2.3
IFNA1 0.9 3.6 1.2
IL12B 0.9 5.9 1.2
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Understanding viral tropism is critical for understand-
ing virus-induced neuropathogenesis. Some viruses, like
Zika virus, preferentially infect neural progenitors [41,
42], whereas human immunodeficiency virus has a
strong affinity for microglial cells [43], JC virus for astro-
cytes [44] and the JHM strain of mouse hepatitis virus
(JHMV) for oligodendrocytes [45]. Flaviviruses such as
TBEV, WNV, and JEV have a preferential tropism for
neurons, a feature that has been observed in human pa-
tients [12, 46, 47], as well as in rodent models [48, 49].
Using human neuronal/glial cultures, we reproduced the
preferential neuronal tropism that is observed in vivo in
showing a high percentage of infected neurons (approxi-
mately 55% at the peak of infection) together with a low
percentage of infected astrocytes (less than 15%). The
limited capacity of the virus to infect astrocytes, as ob-
served in our cultures, as well as in monocultures of ro-
dent or human astrocytes [50–52], may explain the lack
of detection of infected astrocytes in post-mortem brain
tissues from patients with tick-borne encephalitis [12],
or their rare detection in Langat virus-infected mice
[49], as infrequently infected cells are likely to escape de-
tection. Similar observations have been made for other
neurotropic viruses [53–55]. Unexpectedly, we also ob-
served infection of oligodendrocytes in the human neur-
onal/glial cultures, a finding that has never been
reported previously. The in vivo significance of this ob-
servation is at present unknown, especially because the
degree of maturation of oligodendrocytes in our culture
is undefined, the OLIG2 antibody recognizing mature
and immature cells indiscriminately [56]. However, this
should be kept in mind for future examination of brain
tissues from infected patients. As these cells represent
about 5% of the total cell population in our cultures, we
believe them to have a minor impact in vitro and, as we
could not enrich them, they were not further considered
and we confined our study to neurons and astrocytes.
We questioned the reasons that may explain the differ-
ence in TBEV tropism for these two cell types. This may
be due to differential expression of cellular factors that
are necessary for establishing a full viral cycle (entry and
post-entry events), but the similar percentage of infected
neurons and astrocytes that we observed in the first 14 h
following TBEV infection does not lend support for this
hypothesis. An alternative hypothesis would be differen-
tial capacity of the cell types to develop a protective anti-
viral response. The innate immune response, a major
component of the antiviral response, has indeed been
proven to be critically important in restricting infection
by neurotropic viruses [57–59] and in determining
TBEV tropism in different brain areas in murine models
[49, 60]. Also, studies using rodent models have shown
that distinct brain cell types develop different antiviral
states. Microglia and astrocytes, for example, which were
initially considered to be the sole sentinels that respond
to microbial infection within the brain [61, 62] have
been shown to behave differently, as microglia developed
a more robust response than astrocytes to TLR7 activa-
tion [63]. Neurons, long considered to be merely passive
targets, are now known to participate in the antiviral re-
sponse and viral restriction [19–21, 64], and in humans,
neurons and astrocytes have been shown to produce and
Fig. 8 Human astrocytes protect neurons from TBEV infection.
Unsorted cells (Uns-C) and enriched neurons (En-N) were infected
with TBEV (MOI 10−2) and co-immunostained using anti-βIII-tubulin
and anti-TBEV-E3 antibodies. a Percentage of infected neurons
among the neuronal population. Manual enumeration. Data are
expressed as the mean ± SD. b Immunofluorescence staining of
neurons (green). Nuclei were stained with DAPI (blue). Scale bar =
20 μm. Results are representative of two independent experiments
performed in triplicate. Statistical analyses were performed with
Graphpad Prism V6.0.1 using a two-tailed unpaired t test, **p < 0.01
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respond to IFN-α/β. Despite a general assumption that
astrocytes are more important players in antiviral re-
sponse than neurons, the relative contribution of each
cell type has, however, not been formally demonstrated,
as a direct comparison has never been made, whether in
animal or in human in vitro models. Here, we provide
the first evidence that human neurons derived from fetal
neural progenitor cells possess all of the necessary ma-
chinery to mount a cell-intrinsic antiviral response
against TBEV, as they upregulated IFN-β, ISGs, and pro-
inflammatory cytokine mRNAs upon TBEV infection.
We also demonstrated for the first time that human
neurons and astrocytes differ in their capacity to mount
an anti-TBEV response. Differences were indeed ob-
served in the repertoire of the antiviral program that is
activated in the two cell types upon TBEV infection,
with certain genes upregulated in astrocytes but not in
neurons, such as the RSAD2 (encoding viperin) and
TRIM5α genes, two ISGs that have been shown to be
highly important for controlling TBEV [37, 38] and
other flaviviruses [39, 60] in the rodent’s CNS. Quantita-
tive differences were also observed as transcripts encod-
ing PRRs and genes of IFN signaling were upregulated
with different magnitudes in human neurons and astro-
cytes, with a stronger and more durable response in as-
trocytes than in neurons. Our results thus show that the
cell type-specific anti-TBEV response is correlated with
the susceptibility of human neurons and astrocytes to
TBEV, which strongly suggests that the innate antiviral
response is responsible for shaping TBEV tropism in hu-
man brain cells. Such role of innate antiviral response
was previously shown for TBEV and other flaviviruses in
different neuronal sub-types of murine origin [19, 60].
Whether the high neuronal susceptibility to TBEV infec-
tion in the human neuronal/glial cultures is due to a
weaker general antiviral program in human neurons, in-
volving multiple components of the IFN response, from
the PRRs to ISGs, or rather to lower expression of spe-
cific ISGs, such as the RSAD2, IFI6, and TRIM5α genes,
that are dedicated to the control of flaviviruses [30], re-
mains to be elucidated. It also remains to be determined
whether the antiviral response of neurons is weak in re-
sponse to infection by any neurotropic virus, or only by
certain viruses, such as flaviviruses, or whether it is spe-
cific to TBEV infection. Our observation that the base-
line expression of certain antiviral genes is lower in
neurons than in astrocytes may argue in favor of the first
possibility, a hypothesis that should be addressed in fu-
ture studies. In contrast to our results, TBEV infection
in the human neuronal DAOY cells, a human neuro-
blastoma, led to upregulation of the RSAD2 gene [65], a
discrepancy that may be due to the use of non-
physiological, immortalized cells in the study in ques-
tion. Of note, our results showed that neuronal tropism
of TBEV does not depend only on the cell-specific anti-
viral response in human neurons, as the presence of as-
trocytes in the culture limited their infection and
favored their survival. As it was previously reported that
murine astrocytes infected with TBEV were protective to
neurons through IFN signaling [50], and as we showed
that IFNβ was highly upregulated by human astrocytes
upon TBEV infection, we speculate that IFNβ produced
by astrocytes acts in a paracrine manner to restrict neur-
onal infection in our human neuronal/glial co-cultures.
However, it cannot be ruled out that other yet unknown
factors may be involved.
Viral tropism and pathogenesis are intimately
linked, but how the former governs the latter in the
human CNS, during TBEV infection, is incompletely
understood. TBEV preferentially infects and kills the
neurons [12], a highly dramatic event, as neurons
have a very poor capacity to regenerate. Neuronal
death may occur in either direct or indirect manners,
such as, in the latter case, by inducing secretion of
neurotoxic proteins by resident glial cells or recruit-
ment of peripheral inflammatory cells to the brain
parenchyma [11, 14]. Involvement of T cells in neur-
onal death cannot be explored in our model. How-
ever, it should be noted that chemokines such as
CXCL10, CCL5, and CXCL11, which have been
shown to be overexpressed in the cerebrospinal fluid
of human patients infected with TBEV [66–68], are
highly upregulated by both human neurons and astro-
cytes, revealing that the two cell types may participate
in chemo-attraction of T cells into TBEV-infected hu-
man brain parenchyma. Similar to the observation
made for PRRs and ISGs, their upregulation was,
however, stronger in astrocytes than in neurons,
showing that astrocytes may be a major player in this
process as well. Regarding neuronal death due to dir-
ect infection by TBEV, it has not yet been demon-
strated, although ultrastructural changes in response
to TBEV infection have been observed [69, 70]. In
our human neuronal/glial and enriched neuron cul-
tures, neuronal death occurred in the absence of per-
ipheral cells and was associated with infection of a
large proportion of neurons, showing that the virus is
directly responsible for their death. This is likely to
play an important role in the human brain upon in-
fection with TBEV and most probably other flavi-
viruses, since similar conclusions have been drawn for
West Nile virus in studies performed in primary mur-
ine neurons [71]. Reactive astrocytes, however, may
also influence neuronal death. Astrogliosis, indeed,
occurs following brain trauma of diverse etiology [72],
including infection by TBEV or the related Langat
virus infection [12], and may be either beneficial or
detrimental to neurons [73]. In human neuronal/glial
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cultures, we have observed that astrocytes were
hypertrophic, a classical feature of reactive astrocytes
and, when neurons were deprived of astrocytes, they
were more sensitive to TBEV infection, showing that
astrocytes exerted, under these conditions, a neuro-
protective effect, possibly via restriction of neuronal
infection as previously discussed. Thus, the intensity
of neuronal death depends not only on direct infec-
tion of neurons but also on the indirect effect medi-
ated by reactive astrocytes. Proliferation sometimes
accompanied astrocyte hypertrophy in astrogliosis.
Surprisingly, in our experiments, we observed a de-
crease in the number of astrocytes by 7 days following
infection, which strongly suggested that TBEV in-
duced astrocytic death. This is in apparent contradic-
tion with previous work showing that astrocyte
viability was unaffected in rodent and human astro-
cyte monocultures [51, 52]. The difference in our re-
sults may be due to differential conditions of
infection, such as viral strain or infectious dose or to
the presence of neurons in our co-cultures, which
may lead to astrocyte death by an unknown mechan-
ism. Of note, infection with TBEV is not always cor-
related to cell death, since as many as 60% of
oligodendrocytes were infected without impact on
their viability. Why certain cell types die upon TBEV
infection while others do not remains to be under-
stood, as do the molecular pathways that lead to cell
death. Interestingly, our findings suggest that neur-
onal death may result from axonal pathology and
retrograde degeneration. Indeed, we showed that loss
of neurites preceded the disappearance of neuronal
cell bodies, an observation that is in agreement with
previous work in which accumulation of viral protein
in neuritic extensions and dendritic degeneration due
to local replication of TBEV was evidenced in murine
neurons [69]. The relative contribution of axonal de-
generation, which is known to play a pathogenic role
in rabies virus infection [74] and in some neurode-
generative diseases [75], to TBEV-induced neuronal
death need to be defined in future studies.
Conclusions
Until recently, the lack of relevant in vitro models virtu-
ally precluded meaningful study of viral pathogenesis in
the human brain. This obstacle has been overcome by
the development of methodologies providing an unlim-
ited source of human neural cell types that can be used
for disease modeling. In this study, we set up a new,
complex, and highly relevant in vitro model that mimics
the major events of TBEV infection in the human brain.
Using this model, we evidenced differential innate im-
mune responses in human neurons and astrocytes that
contribute to shaping TBEV tropism and
neuropathogenesis. Based on our results, we propose a
model for interactions between TBEV and human brain
cells that is represented in Fig. 9. Our study thus ad-
vances understanding of the mechanisms involved in
TBEV-induced damage of the human brain and provides
a pathological model that can be used in the future to
provide greater knowledge as well as to develop new
therapies by screening for antiviral or neuroprotective
drugs.
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Fig. 9 Proposed model of interactions between TBEV and human
brain cells. In the human brain parenchyma, TBEV infects neurons,
astrocytes, and possibly oligodendrocytes (1). Both neurons and
astrocytes develop an antiviral response. In neurons, it is insufficient
to afford protection (2) and poorly controlled infection induces
neuronal death in a direct manner (3). Astrocytes are infected but
control infection, owing to their strong antiviral response (4), which
may also be beneficial to neurons (5). Astrocytes enter a reactive
stage (6) and some of them die (7). Both neurons and astrocytes
overexpressed a high level of chemokines involved in chemo-
attraction of T cells in the brain parenchyma (8), although astrocytes
are stronger producers. The figure was created using Servier Medical
Art available on www.servier.com. As, astrocytes; AV Resp, antiviral
response; CMK, chemokines; Ne, neurons
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are expressed as the mean ± SD and normalized to non-infected Uns-C.
Results are representative of two independent experiments performed in
triplicate. Statistical analysis was performed using a two-tailed unpaired t
test with GraphPad Prism V6.0.1, ns = non-significant (p > 0.05).
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